NCT04966676 2026-01-08
ATLAS
University Health Network, Toronto
Phase 2 Terminated
Clinical Trials
7 trialsNCT03274258 2025-12-03
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05199285 2025-10-03
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
Academic and Community Cancer Research United
Phase 2 Terminated
NCT02203604 2023-07-18
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT02892734 2020-07-16
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Northwestern University
Phase 2 Terminated
NCT01970527 2020-02-13
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
University of Washington
Phase 2 Terminated
NCT01740401 2017-12-06
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated